Your browser is no longer supported. Please, upgrade your browser.
FIXX Homology Medicines, Inc. daily Stock Chart
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-2.79 Insider Own5.41% Shs Outstand45.21M Perf Week-5.07%
Market Cap474.07M Forward P/E- EPS next Y-2.97 Insider Trans0.00% Shs Float42.77M Perf Month-7.42%
Income-124.50M PEG- EPS next Q-0.81 Inst Own98.00% Short Float10.35% Perf Quarter-35.25%
Sales2.20M P/S215.49 EPS this Y-26.80% Inst Trans0.08% Short Ratio9.16 Perf Half Y-16.96%
Book/sh4.31 P/B2.48 EPS next Y6.30% ROA-42.40% Target Price- Perf Year-18.05%
Cash/sh4.65 P/C2.29 EPS next 5Y-9.40% ROE-53.10% 52W Range9.19 - 22.50 Perf YTD-48.45%
Dividend- P/FCF- EPS past 5Y- ROI-42.50% 52W High-52.58% Beta-
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low16.10% ATR0.63
Employees197 Current Ratio10.70 Sales Q/Q50.00% Oper. Margin- RSI (14)46.33 Volatility5.17% 5.79%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.20% Profit Margin- Rel Volume0.68 Prev Close10.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume483.29K Price10.67
Recom1.50 SMA20-3.09% SMA50-2.25% SMA200-26.35% Volume329,463 Change-2.56%
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Oct-19-20 03:35PM  
Oct-16-20 04:53PM  
Oct-15-20 01:33PM  
01:30PM  
12:00PM  
11:53AM  
11:30AM  
Oct-14-20 06:23PM  
05:28PM  
Oct-13-20 08:20PM  
04:30PM  
03:12PM  
02:55PM  
01:49PM  
10:55AM  
Oct-12-20 06:10PM  
05:00PM  
Oct-09-20 10:13PM  
04:15PM  
Oct-08-20 09:44PM  
Sep-18-20 09:00AM  
Aug-10-20 05:35PM  
04:05PM  
12:39PM  
12:38PM  
Aug-06-20 12:30PM  
Jul-27-20 11:42PM  
Jul-21-20 08:00AM  
Jul-08-20 08:49AM  
Jun-29-20 10:49AM  
Jun-27-20 02:58PM  
May-26-20 02:11PM  
May-19-20 04:08PM  
May-12-20 08:00AM  
May-10-20 09:45AM  
May-07-20 04:05PM  
Apr-29-20 08:00AM  
Apr-03-20 09:44AM  
Mar-16-20 09:00AM  
Mar-14-20 09:14AM  
Mar-12-20 05:45PM  
04:10PM  
Mar-11-20 09:22AM  
Mar-03-20 12:30PM  
Feb-20-20 09:00AM  
Feb-17-20 10:06AM  
Feb-13-20 09:00AM  
Jan-31-20 11:52AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
Jan-10-20 02:20PM  
Jan-01-20 08:01AM  
Dec-24-19 10:49AM  
Dec-18-19 10:23AM  
07:23AM  
Dec-17-19 04:01PM  
Dec-16-19 09:00AM  
Dec-13-19 02:44PM  
Dec-03-19 08:30AM  
Nov-26-19 03:00PM  
Nov-12-19 07:35PM  
04:09PM  
Nov-05-19 10:32AM  
Oct-28-19 08:07PM  
Oct-25-19 08:30AM  
Oct-21-19 08:30AM  
Sep-30-19 08:49AM  
Sep-27-19 07:37AM  
Sep-03-19 08:30AM  
Aug-08-19 04:15PM  
Aug-05-19 10:31AM  
Aug-01-19 08:30AM  
Jul-15-19 04:01PM  
Jun-27-19 04:01PM  
Jun-25-19 01:45PM  
Jun-17-19 07:05AM  
Jun-13-19 08:30AM  
Jun-10-19 08:30AM  
May-14-19 09:00AM  
May-13-19 05:55PM  
04:50PM  
04:15PM  
May-09-19 08:45PM  
08:30AM  
May-06-19 10:30AM  
May-02-19 08:00AM  
Apr-30-19 12:00PM  
Apr-15-19 01:05PM  
Apr-09-19 07:08PM  
Apr-08-19 04:10PM  
Apr-04-19 04:05PM  
07:00AM  
Apr-02-19 07:12AM  
Mar-19-19 08:39AM  
Mar-12-19 07:30AM  
07:13AM  
Mar-06-19 08:30AM  
Mar-01-19 05:38PM  
Jan-07-19 09:25AM  
08:30AM  
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Timothy PSee RemarksMar 17Sale13.011,31517,1090Mar 18 05:32 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Option Exercise0.6312,0007,57912,000Feb 05 04:06 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Sale16.1612,000193,8660Feb 05 04:06 PM
TZIANABOS ARTHURPresident & CEOFeb 03Sale16.1612,500202,02177,505Feb 05 04:05 PM
Flynn James EPossible Member of 10% GroupJan 30Sale15.45509,9707,879,0370Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 29Sale15.458,857136,808509,970Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 28Sale15.5165,8911,021,936518,827Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 27Sale15.77193,3593,049,600584,718Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 24Sale15.69380,2565,965,000778,077Jan 28 06:38 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Option Exercise0.636,0003,7906,000Jan 03 05:32 PM
TZIANABOS ARTHURPresident & CEOJan 02Sale20.5012,500256,19190,005Jan 03 05:36 PM
Seymour AlbertChief Scientific OfficerJan 02Sale20.509,133187,216154,017Jan 03 05:33 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Sale20.506,000122,9840Jan 03 05:32 PM
Flynn James EPossible Member of 10% GroupDec 24Sale21.95350,0007,682,5351,766,106Dec 27 07:09 PM
Flynn James EPossible Member of 10% GroupDec 23Sale21.83130,9792,859,1931,917,339Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 20Sale21.5021,129454,2781,973,934Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 19Sale21.6812,622273,5891,983,064Dec 23 07:57 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Seymour AlbertChief Scientific OfficerDec 02Sale16.239,300150,970163,150Dec 03 04:05 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Sale16.216,00097,2660Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEODec 02Sale16.2512,500203,176102,505Dec 03 04:06 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Sale16.006,00096,0000Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEONov 29Sale16.0412,500200,559115,005Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerNov 29Sale16.069,300149,390172,450Dec 03 04:05 PM
Gregory Richard J.DirectorNov 18Option Exercise0.0310,80632410,806Jan 29 06:43 PM